Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 8382: Body Mass Index and Thromboembolic, Cardiovascular, and Mortality Outcomes in Patients with Atrial Fibrillation: A Real-World Propensity-Matched Analysis

Background: Body mass index (BMI) is strongly associated with cardiovascular outcomes in patients with atrial fibrillation (AF). Although obesity is a recognized risk factor for AF development, emerging evidence suggests the presence of an "obesity paradox," where higher BMI may be associated with improved outcomes...

H. Alhammouri, F. Qtaishat, J. Yasin et al. · 0 citations
Nov 2026

Abstract 9771: Cardiovascular and Mortality Outcomes Associated with GLP-1 Receptor Agonists Among Adults with Prediabetes: A Propensity-Matched Real-World Cohort Study

Introduction: Prediabetes is a growing global health burden associated with elevated cardiovascular risk well before overt diabetes. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) confer cardiovascular benefit in type 2 diabetes and obesity, real-world data in overweight or obese adults with prediabet...

F. Qtaishat, H. Alhammouri, J. Yasin et al. · 0 citations
Nov 2026

Abstract 14489: GLP-1 Receptor Agonists vs. SGLT2 Inhibitors and Risk of Atrial Fibrillation in Patients with Obstructive Sleep Apnea and Obesity: A Propensity-Matched Analysis

Introduction: Obstructive sleep apnea (OSA) and obesity are established risk factors for atrial fibrillation (AF) through shared mechanisms including chronic intermittent hypoxia, sympathetic activation, and atrial remodeling. GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) are increasingly used in...

Zaid Al-Kofahi, H. Alhammouri, F. Qtaishat et al. · 0 citations
Nov 2026

Abstract 16799: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Prior Myocardial Infarction and Overweight or Obesity: A Propensity-Matched Analysis

In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality.

Zaid Al-Kofahi, H. Alhammouri, F. Qtaishat et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.